Cardiac dysfunction is the most frequent cause of morbidity and mortality in amyloid light chain (AL) amyloidosis caused by a clonal immunoglobulin light chain (LC). Previously published transgenic animal models of AL amyloidosis have not recapitulated the key phenotype of cardiac dysfunction seen in AL amyloidosis, which has limited our understanding of the disease mechanisms in vivo, as well as the development of targeted AL therapeutics. We have developed a transgenic zebrafish model in which a λ LC derived from a patient with AL amyloidosis is conditionally expressed in the liver under the control of the Gal4 upstream activation sequence enhancer system. Circulating LC levels of 125 µg/ml in these transgenic zebrafish are comparable to median pathological serum LC levels. Functional analysis links abnormal contractile function with evidence of cellular and molecular proteotoxicity in the heart, including increased cell death and autophagy. However, despite pathological and functional phenotypes analogous to human AL, the lifespan of the transgenic fish is comparable to control fish without the expressed AL-LC transgene. Nuclear labeling experiments suggest increased cardiac proliferation in the transgenic fish, which can be counteracted by treatment with a small molecule proliferation inhibitor leading to increased zebrafish mortality because of cardiac apoptosis and functional deterioration. This transgenic zebrafish model provides a platform to study underlying AL disease mechanisms in vivo further.NEW & NOTEWORTHY Heart failure is a major cause of mortality in amyloid light (AL) amyloidosis, yet it has been difficult to model in animals. We report the generation of a transgenic zebrafish model for AL amyloidosis with pathological concentration of circulating human light chain protein that results in cardiac dysfunction. The light chain toxicity triggers regeneration in the zebrafish heart resulting in functional compensation early in life, but with age develops into cardiac dysfunction.
Epilepsy is one of the most prevalent chronic medical conditions that really can affect individuals at any age. A broader study of the pathogenesis of the epileptic condition will probably serve as the cornerstone for the development of new antiepileptic remedies that aim to treat epilepsy symptomatically as well as prevent the epileptogenesis process or regulate its progression. Cellular changes in the brain include oxidative stress, neuroinflammation, inflammatory cell invasion, angiogenesis, and extracellular matrix associated changes. The extensive molecular profiling of epileptogenic tissue has revealed details on the molecular pathways that might start and sustain cellular changes. In healthy brains, epilepsy develops because of vascular disruptions, such as blood–brain barrier permeability and pathologic angiogenesis. Key inflammatory mediators are elevated during epileptic seizures, increasing the risk of recurrent seizures and resulting in secondary brain injury. Prostaglandins and cytokines are well-known inflammatory mediators in the brain and, after seizures, their production is increased. These inflammatory mediators may serve as therapeutic targets in the clinical research of novel antiepileptic medications. The functions of inflammatory mediators in epileptogenesis are covered in this review. Oxidative stress also plays a significant role in the pathogenesis of various neurological disorders, specifically epilepsy. Antioxidant therapy seems to be crucial for treating epileptic patients, as it prevents neuronal death by scavenging excess free radicals formed during the epileptic condition. The significance of antioxidants in mitochondrial dysfunction prevention and the relationship between oxidative stress and inflammation in epileptic patients are the major sections covered in this review.
26 September 2025 in Journal of Biochemical and Molecular Toxicology
Sepsis, a potentially lethal organ dysfunction caused by dysregulated host response to infection, occurs in more than 30 million patients annually worldwide. Sepsis-associated encephalopathy (SAE) is an early and common complication, manifesting as acute delirium and coma, and often resulting in long-term cognitive dysfunction. This review distils current knowledge of the intricate pathophysiology of sepsis-induced brain dysfunction. The aetiology is multifactorial, resulting from a severe systemic inflammatory response that compromises the blood-brain barrier (BBB) and permits peripheral inflammatory mediators to access the central nervous system. This initiates severe neuroinflammation through microglial and astrocytic activation, accompanied by oxidative stress, resulting in severe mitochondrial dysfunction and a state of "cytopathic hypoxia". In addition, sepsis causes severe dysregulation of key neurotransmitter systems, including excitotoxic glutamate accumulation and dysfunctional cholinergic transmission, and disrupts hormonal homeostasis via the hypothalamic-pituitaryadrenal (HPA) axis. Despite these elaborate descriptions, diagnostic strategies for SAE remain primarily based on clinical examination, and therapeutic interventions are limited to treating the underlying sepsis. This decision is underpinned by controversy regarding adjunctive treatments, such as corticosteroids and sedation. This review identifies the imperative requirement for specific diagnostic biomarkers and neuroprotective interventions to reduce the high morbidity and mortality of SAE and post-sepsis cognitive dysfunction.